Effects of Preoperative &bgr;-Blocker Use on Clinical Outcomes after Coronary Artery Bypass Grafting: A Report from the Japanese Cardiovascular Surgery Database

Background:The authors evaluated the effect of preoperative &bgr;-blocker use on early outcomes in patients undergoing coronary artery bypass grafting (CABG) in Japan. Methods:The authors analyzed 34,980 cases of isolated CABGs, performed between 2008 and 2011, at the 333 sites recorded in the Japanese Cardiovascular Surgical Database. In addition to the use of multivariate models, a one-to-one matched analysis, based on estimated propensity scores for patients with or without preoperative &bgr;-blocker use, was performed. Results:The study population (mean age, 68 yr) comprised 20% women, and &bgr;-blockers were used in 10,496 patients (30%), who were more likely to have risk factors and comorbidities than patients in whom &bgr;-blockers were not used. In the &bgr;-blocker and non-&bgr;-blocker groups, the crude in-hospital mortality rate was 1.7 versus 2.5%, whereas the composite complication rate was 9.7 versus 11.6%, respectively. However, after adjustment, preoperative &bgr;-blocker use was not a predictor of in-hospital mortality (odds ratio, 1.00; 95% CI, 0.82 to 1.21) or complications (odds ratio, 0.99; 95% CI, 0.91 to 1.08). When the outcomes of the two propensity-matched patient groups were compared, differences were not seen in the 30-day operative mortality (1.6 vs. 1.5%, respectively; P = 0.49) or postoperative complication (9.8 vs. 9.7%; P = 1.00) rates. The main findings were broadly consistent in a subgroup analysis of low-risk and high-risk groups. Conclusion:In this nationwide registry, the use of preoperative &bgr;-blockers did not affect short-term mortality or morbidity in patients undergoing CABG.

[1]  Biykem Bozkurt,et al.  2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[2]  L. Fleisher,et al.  Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice , 2014, Journal of the American College of Cardiology.

[3]  N. Weitzel,et al.  Perioperative Medicine , 2021, ASA Monitor.

[4]  W. Henderson,et al.  Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. , 2013, JAMA.

[5]  C. O'connor,et al.  Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). , 2013, The American journal of cardiology.

[6]  Deepak L. Bhatt,et al.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. , 2012, JAMA.

[7]  Janet S. Wright,et al.  2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi , 2011, Journal of the American College of Cardiology.

[8]  M. Mack,et al.  Preoperative beta-blocker usage: is it really worthy of being a quality indicator? , 2011, The Annals of thoracic surgery.

[9]  J. McMurray,et al.  Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. , 2011, Journal of the American College of Cardiology.

[10]  B. Gersh Lack of Effect of Oral Beta-Blocker Therapy at Discharge on Long-Term Clinical Outcomes of ST-Segment Elevation Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention , 2011 .

[11]  Y. Hayashi,et al.  Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. , 2010, The American journal of cardiology.

[12]  A. Wallace,et al.  Association of the Pattern of Use of Perioperative &bgr;-Blockade and Postoperative Mortality , 2010, Anesthesiology.

[13]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[14]  Volkmar Falk,et al.  Guidelines on myocardial revascularization. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  William Wijns,et al.  Experience with revascularization procedures does matter: low volume means worse outcome. , 2010, European heart journal.

[16]  P. Fitzgerald,et al.  SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. , 2010, The American journal of cardiology.

[17]  Takeshi Kimura,et al.  Difference in patient profiles and outcomes in Japanese versus American patients undergoing coronary revascularization (collaborative study by CREDO-Kyoto and the Texas Heart Institute Research Database). , 2010, The American journal of cardiology.

[18]  R. Nagai,et al.  Beta-blocker prescription among Japanese cardiologists and its effect on various outcomes. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[19]  H. Miyata,et al.  First report on 30-day and operative mortality in risk model of isolated coronary artery bypass grafting in Japan. , 2008, The Annals of thoracic surgery.

[20]  Denis Xavier,et al.  Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial , 2008, The Lancet.

[21]  Teruhisa Kazui,et al.  Thoracic and cardiovascular surgery in Japan during 2004. , 2006, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[22]  Teruhisa Kazui,et al.  Thoracic and cardiovascular surgery in Japan during 2004. , 2006, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[23]  R. Collins,et al.  Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[24]  G. Guyatt,et al.  Are the recommendations to use perioperative β-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? , 2004, Canadian Medical Association Journal.

[25]  H. Ogawa,et al.  Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. , 2003, The American journal of cardiology.

[26]  E. Peterson,et al.  Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. , 2002, JAMA.

[27]  A. Wood Racial differences in the response to drugs--pointers to genetic differences. , 2001, The New England journal of medicine.

[28]  Jeroen J. Bax,et al.  Predictors of Cardiac Events After Major Vascular Surgery Role of Clinical Characteristics, Dobutamine Echocardiography, and b-Blocker Therapy , 2001 .

[29]  R. Mongiardo,et al.  Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. , 2000, Circulation.

[30]  A. Maseri,et al.  Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. , 1999, Journal of the American College of Cardiology.

[31]  Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. , 1995, European heart journal.

[32]  B. Psaty,et al.  The Relative Risk of Incident Coronary Heart Disease Associated with Recently Stopping the Use of ??-Blockers , 1991 .

[33]  B. Psaty,et al.  The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. , 1990, JAMA.

[34]  G R Wilkinson,et al.  Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. , 1989, The New England journal of medicine.

[35]  S. Nattel,et al.  Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule. , 1982, The American journal of cardiology.

[36]  L Goldman,et al.  Multifactorial index of cardiac risk in noncardiac surgical procedures. , 1977, The New England journal of medicine.

[37]  Jacob Cohen The t Test for Means , 1977 .

[38]  R. Miller,et al.  Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. , 1975, The New England journal of medicine.